Prof. Zhongguo Zhou 周仲国
Chief Physician, Professor
Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive treatment for liver cancer, including laparoscopic resection and ablation. Systemic therapy for advanced liver cancer, including chemotherapy, targeted therapy, and immunotherapy.
Dr. Zhou holds a bachelor's degree from Sun Yat-sen University (2001-2006) and a joint PhD from MD Anderson Cancer Center and Sun Yat-sen University (2006-2011). Dr. Zhou completed postdoctoral research at Scripps Research Institute (2018-2019) and was a visiting scholar at the University of California. Dr. Zhou serves as a doctoral supervisor and principal professor.
Professional roles
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Minimally Invasive Intervention Youth Committee, Guangdong Anti-Cancer Association
- Member, Liver Cancer Professional Committee, Guangdong Anti-Cancer Association
- Member, Comprehensive Treatment Professional Committee, Guangdong Liver Disease Society
Name order: in Chinese the family name comes first (Zhou Zhongguo). Papers usually list the name as Zhongguo Zhou or Zhou Z.
Selected publications
123 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- Hepatobiliary Pancreat Dis Int, 2026 (senior author): FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study. PubMed 42618446
- J Clin Invest, 2026 (senior author): Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma. PubMed 41926218
- Int J Cancer, 2025 (senior author): Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study. PubMed 39834172
- Int J Surg, 2025 (senior author): Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study. PubMed 39110571
- J Hepatocell Carcinoma, 2024 (senior author): Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy. PubMed 38463545
- J Hepatocell Carcinoma, 2023 (senior author): Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy. PubMed 38058386
- J Hepatocell Carcinoma, 2023 (senior author): Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy. PubMed 38053944
- Cancer Res, 2022 (senior author): PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. PubMed 35802648
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion